Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(14 sites)
Japan
Aichi Cancer Center Hospital, Nagoya, Aichi-ken Nagoya University Hospital, Nagoya, Aichi-ken Akita University Hospital, Akita, Akita National Cancer Center Hospital East, Kashiwa-shi, Chiba Kyushu University Hospital, Fukuoka, Fukuoka Hokkaido University Hospital, Sapporo, Hokkaido Tokai University Hospital, Isehara-shi, Kanagawa Kumamoto University Hospital, Kumamoto, Kumamoto University Hospital Kyoto Prefectural University of Medicine, Kyoto, Kyoto Tohoku University Hospital, Sendai, Miyagi Okayama University Hospital, Okayama, Okayama-ken Kindai University Hospital, Osaka Sayama-shi, Osaka Osaka University Hospital, Osaka-fu, Osaka Cancer Institute Hospital of JFCR, Koto-ku, Tokyo